Med. Pro Praxi 2009; 6(2): 85-89

Erythema nodosum

MUDr. Andrea Hradiská
Kožní oddělení, Uherskohradišťská nemocnice a.s

Erythema nodosum is the most common type of septal panniculitis. It may occur separately or as a part of wide range of many diseases

such as infections, sarcoidosis, inflammatory bowel diseases, malignancies, autoimmune disorders, medications, pregnancy. Erythema

nodosum is considered to be a delayed hypersensitivity response to a variety of antigenic stimuli. The incidence of erythema nodosum

is 1–5 in 100 000 population per year, with women between the ages of 15 and 40 years being most commonly affected. It is typically

presents as an acute eruption of erythematous, tender subcutaneous nodules over the pretibial areas bilaterally. The nodules subsequently

change the color from merely yellow to green, which resembles a deep bruise, the so–called erythema contusiforme. Onset of the disease

may be accompanied by fever, fatigue, malaise, arthralgia, headache or other systemic manifestations. The eruption generally lasts from

3 to 6 weeks, ulceration is never seen. The lesions heal without atrophy or scarring. Erythema nodosum is histologic example of a septal

panniculitis with no vasculitis. Treatment of erythema nodosum is influenced by underlying condition. Nodules of erythema nodosu

regress spontaneously within a few weeks, and bed rest is often sufficient treatment. Nonsteroidal anti-inflammatory drugs are used

in mild cases of a self-limited erythema nodosum. Systemic corticosteroids are rarely indicated in erythema nodosum and before these

drugs are administered an underlying infection and malignancy should be ruled out. If the erythema nodosum occurs in an association

with other diseases, we treat the underlying disease.

Keywords: erythema nodosum, aetiology, Löfgren syndrom, differential diagnosis, treatment.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradiská A. Erythema nodosum. Med. praxi. 2009;6(2):85-89.
Download citation

References

  1. Braun-Falco O, Plewig G, Wolf HH. Dermatológia a venerológia, 1. slovenské a české vydanie. Martin: Osveta, 2001: 483-485.
  2. Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk P. Erythema nodosum: an experience of 10 years. Scand J Infect Dis 2004; 36: 424-427. Go to original source... Go to PubMed...
  3. Štork J, Arenberger P, Pizinger K, Semrádová V, Vosmík F. Dermatovenerologie, první vydání. Praha: Galén, 2008: 245 s.
  4. Sanders CJ, Hulsmans RF. Persistent erythema nodosum and asymptomatic Campylobacter infection. J Am Acad Dermatol 1991; 24: 285-286. Go to original source... Go to PubMed...
  5. Garcia PC, Gonzalez-Gay MA, Vazquez CM. Erythema nodosum. Etiologie and predictive factors in defined population. Art kritic Rheum 2000; 43: 584-592. Go to original source...
  6. Yang SG, Han KH, Cho KH, Lee AY. Development of EN in the sourse of oestrogen replacement therapy. Br J Dermatol 1997; 137: 319-320.
  7. Ricci RM, Deering KC. Erythema nodosum caused by omeprazol. Cutis 1996; 57(6): 434. Go to PubMed...
  8. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkins disease. Int J Dermatol, 2006; 45: 251-256. Go to original source... Go to PubMed...
  9. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohns disease. Can J Gastroenterol 2005; 19: 603-606. Go to original source... Go to PubMed...
  10. Kumar B, Sandhu K. Erythema nodosum and antitubercular therapy. J Dermatol Treat 2004; 15: 218-221. Go to original source... Go to PubMed...
  11. Kolibášová K, Hegyi V, Hegyi E. Ošetrovanie a liečenie kožných a pohlavných chorôb, Prvé vydanie. Bratislava: Hegprof, 1994: 211 s.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.